Do Recent Changes in Medical Therapy Alter the Prognosis in Coronary Heart Disease?

1982 ◽  
pp. 65-70
Author(s):  
K. Bachmann
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Medical Therapy

scholarly journals Intensity of Guideline-Directed Medical Therapy for Coronary Heart Disease and Ischemic Heart Failure Outcomes

2020 ◽  
Author(s):  
Rebecca Crosier ◽  
Peter C. Austin ◽  
Dennis T. Ko ◽  
Patrick R. Lawler ◽  
Therese A. Stukel ◽  
...  
Keyword(s):  
Heart Failure ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Medical Therapy ◽  
Ischemic Heart ◽  
Ischemic Heart Failure

Predictors and Outcomes of Routine Versus Optimal Medical Therapy in Stable Coronary Heart Disease

2015 ◽  
Vol 116 (5) ◽  
pp. 671-677 ◽  
Author(s):  
Soohun Chun ◽  
Feng Qiu ◽  
Peter C. Austin ◽  
Dennis T. Ko ◽  
Muhammad Mamdani ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Medical Therapy ◽  
Optimal Medical Therapy ◽  
Stable Coronary Heart Disease

scholarly journals Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization?

2019 ◽  
Vol 91 (12) ◽  
pp. 129-134
Author(s):  
O L Barbarash ◽  
V V Kashtalap
Keyword(s):  
Clinical Trial ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Acetylsalicylic Acid ◽  
Medical Therapy ◽  
Antithrombotic Therapy ◽  
Review Article ◽  
Real Situation ◽  
Chronic Coronary Heart Disease

In the review article are provided the approaches to the therapy for improvement of prognosis in patients with peripheral and multifocal atherosclerosis which are available now; some limitations and a real situation are designated for the antithrombotic therapy in this category of patients. According to the clinical trial COMPASS the prospects of wide use of a combination of acetylsalicylic acid and a rivaroxsaban of 2.5 mg 2 times a day in the patients with chronic coronary heart disease and/or symptom peripheral atherosclerosis are designated.

Sign in / Sign up

Export Citation Format

Share Document